UroGen Pharma Ltd. (LON:0XOD)

Market Cap	725.25M +104.7%
Revenue (ttm)	71.80M +8.0%
Net Income	-122.48M
EPS	-2.57
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	197
Average Volume	1,534
Open	21.68
Previous Close	21.81
Day's Range	20.44 - 22.15
52-Week Range	3.61 - 29.78
Beta	1.30
RSI	47.07
Earnings Date	Mar 13, 2026

About UroGen Pharma

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscl...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 287
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0XOD

Financial Performance

In 2024, UroGen Pharma's revenue was $90.40 million, an increase of 9.29% compared to the previous year's $82.71 million. Losses were -$126.87 million, 24.1% more than in 2023.

Financial numbers in USD